Leveraging BTK Inhibition Strategies in B-Cell Malignancies: Expert Perspectives to Guide Clinical Decisions

Source: BTK Inhibitors in B-Cell Malignancies: Expert Perspectives to Guide Clinical Decisions
Download Slideset
Download this slideset from our live meeting series to learn more about the optimal use of BTK inhibitors as therapy for patients with B-cell malignancies, including MCL, CLL/SLL, WM and MZL.
Jeremy S. Abramson, MD, MMSc
Christopher R. Flowers, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 1.24 MB
Released: June 26, 2020

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings